| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SOX18 |
| Uniprot No | P35713 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-384aa |
| 氨基酸序列 | MQRSPPGYGA QDDPPARRDC AWAPGHGAAA DTRGLAAGPA ALAAPAAPAS PPSPQRSPPR SPEPGRYGLS PAGRGERQAA DESRIRRPMN AFMVWAKDER KRLAQQNPDL HNAVLSKMLG KAWKELNAAE KRPFVEEAER LRVQHLRDHP NYKYRPRRKK QARKARRLEP GLLLPGLAPP QPPPEPFPAA SGSARAFREL PPLGAEFDGL GLPTPERSPL DGLEPGEAAF FPPPAAPEDC ALRPFRAPYA PTELSRDPGG CYGAPLAEAL RTAPPAAPLA GLYYGTLGTP GPYPGPLSPP PEAPPLESAE PLGPAADLWA DVDLTEFDQY LNCSRTRPDA PGLPYHVALA KLGPRAMSCP EESSLISALS DASSAVYYSA CISG |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SOX18重组蛋白的模拟参考文献示例(注：部分信息为示例性概括，实际文献需根据具体研究查询)：
1. **"SOX18 Recombinant Protein Promotes Angiogenesis via VEGF Signaling Pathway"**
*Authors: Young, L., et al. (2015)*
**摘要**: 研究报道了人源SOX18重组蛋白在体外血管生成中的作用，证实其通过激活VEGF信号通路促进内皮细胞迁移和管状结构形成，为缺血性疾病治疗提供潜在靶点。
2. **"Structural Characterization of SOX18 DNA-Binding Domain by X-ray Crystallography"**
*Authors: Smith, R., et al. (2018)*
**摘要**: 首次解析了SOX18重组蛋白DNA结合域的高分辨率晶体结构，揭示了其与靶DNA序列的特异性结合模式，为突变导致的遗传性水肿疾病机制提供结构基础。
3. **"Recombinant SOX18 Mutants Impair Lymphatic Development in Zebrafish Model"**
*Authors: Kumar, A., et al. (2020)*
**摘要**: 通过构建SOX18重组突变蛋白(R136C和R211Q)，在斑马鱼模型中验证了突变体对淋巴管发育的显性负效应，解释了人类低淋巴水肿综合征的分子病理机制。
4. **"High-Yield Expression and Purification of SOX18 in E. coli for Functional Screening"**
*Authors: Chen, X., et al. (2022)*
**摘要**: 开发了一种优化的大肠杆菌表达系统，实现SOX18重组蛋白的高效可溶性表达，并通过凝胶迁移实验(EMSA)验证其体外DNA结合活性，为高通量药物筛选奠定基础。
(提示：实际文献需通过PubMed或Web of Science以关键词"SOX18 recombinant protein"检索，重点关注其分子功能、疾病关联或结构研究。)
**Background of SOX18 Recombinant Protein**
SOX18. a member of the SOX (SRY-related high-mobility group [HMG] box) transcription factor family, plays critical roles in developmental processes, particularly in vascular and lymphatic system formation. It belongs to the SOXF subgroup (SOX7. SOX17. SOX18) and regulates gene expression by binding to DNA via its conserved HMG domain, facilitating cell fate determination and tissue morphogenesis. SOX18 is notably involved in angiogenesis, lymphangiogenesis, and endothelial cell differentiation, interacting with pathways like VEGF and Notch. Mutations in *SOX18* are linked to human disorders, including hypotrichosis-lymphedema-telangiectasia syndrome and vascular dysplasia.
Recombinant SOX18 protein is engineered *in vitro* using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research. It typically includes tags (e.g., His-tag) for isolation and may retain DNA-binding activity, enabling studies on its molecular mechanisms. Researchers use it to investigate SOX18’s role in transcriptional regulation, its synergy with co-factors (e.g., MEF2C), and its impact on diseases like cancer metastasis or lymphedema.
The protein also serves as a tool for drug screening, aiming to modulate SOX18 activity in pathological angiogenesis or lymphatic disorders. Its study contributes to therapeutic strategies for cardiovascular diseases, wound healing, and regenerative medicine. Despite progress, challenges remain in understanding context-specific interactions and post-translational modifications, highlighting the need for high-quality recombinant SOX18 in functional assays.
×
